Clinical Study

4202-Hvs-101- A Randomized, Placebo-Controlled, Double Blind, Single Ascending And Multiple Ascending Dose Study To Assess The Safety, Pharmacokinetics And Pharmacodynamics Of Ft-4202 In Healthy Volunteers And Sickle Cell Disease Patients.

Posted Date: Nov 7, 2019

  • Investigator: Hyon Kim
  • Specialties:
  • Type of Study: Drug

The goal of this study is to evaluate the safety and tolerability of a single ascending dose and multiple ascending doses of FT-4202 in healthy volunteers and sickle cell disease (SCD) patients.

Criteria:

To Be Eligible: Nonpregnant/Nonbreastfeeding, No Hiv Or Hepatitis, 12-50 Yrs Of Age, >40Kg, Systolic Bp 90-150 Mmhg, Diastolic 50-95 Mmhg, No Severe Co-Morbitities

Keywords:

Sickle Cell

For More Information:

Uc Cancer Institute
513-584-7698
cancer@uchealth.com


  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at ResearchStudies@UCHealth.com or (513) 245-3417.